Estrogen receptor ligand treatment for neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-11628146-B2
Application number	US-202016938577-A
Country	US
Kind code	B2
Filing date	Jul 24, 2020
Priority date	Sep 2, 2014
Publication date	Apr 18, 2023
Grant date	Apr 18, 2023

Abstract

The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

First claim

What is claimed is:

1. A method of slowing cerebral cortex gray matter atrophy and ameliorating symptoms of multiple sclerosis in a subject suffering from multiple sclerosis, comprising administering to the subject an estrogen receptor beta ligand.

2. The method of claim 1 , wherein the subject has greater than about 0.1% brain gray matter atrophy per annum.

3. The method of claim 1 , wherein the brain gray matter atrophy per annum is about 0.2%, or about 0.3%, or about 0.4%, or about 0.5%, or about 0.6%, or about 0.7%, or about 0.8%, or about 0.9%, or about 1.0%, or about 1.1%, or about 1.2%, or about 1.3%, or about 1.4%, or about 1.5%, or about 2.0%.

4. The method of claim 1 , wherein the method reduces the gray matter atrophy.

5. The method of claim 1 , wherein the gray matter atrophy is measured using an imaging technique or surrogate marker.

6. The method of claim 1 , wherein the gray matter atrophy is measured by MRI.

7. The method of claim 1 , wherein the estrogen receptor beta ligand is administered on a daily basis.

8. The method of claim 1 , wherein the estrogen receptor beta ligand is conjointly administered with an immunotherapeutic agent, and wherein the immunotherapeutic agent is interferon-beta Ia, interferon-beta 1b, pegylated interferon-beta-Ia, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, mycophenolate mofetil, paclitaxel, cyclosporine, corticosteroids, azathioprine, cyclophosphamide, methotrexate, cladribine, 4-aminopyridine, and tizanidine.

9. The method of claim 1 , wherein the subject is female.

Assignees

• Univ California

Inventors

• Voskuhl Rhonda R

Classifications

• A61K31/05 Primary

  Phenols {(cannabinoids A61K31/658)} · CPC title

• C07C39/42

  containing six-membered aromatic rings and other rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• C07D307/93

  condensed with a ring other than six-membered · CPC title